Tag Archives: ivacaftor

November, 2018

October, 2018

August, 2018

April, 2018

December, 2017

August, 2017

July, 2017

  • 19 July

    Vertex Announces Positive Results for Cystic Fibrosis Triple Combos

    BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min). These are the first data to demonstrate the potential to treat the underlying …

May, 2017

October, 2016

August, 2016

  • 17 August

    Vertex to Stop of Experimental Cystic Fibrosis Phase 3 Combo Trial

    BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies that together are expected to enroll more than 1,000 people with cystic fibrosis (CF). Based on a planned interim futility …